UCB – Belgium

Last updated: 01.02.2019


UCB is a global biopharmaceutical company headquartered in Brussels, Belgium that focuses on neurology and immunology.

The company has more than 7,5000 employees, a strong market presence in about 40 countries, € 4.5 billion in revenue (2017) and numerous strategic partnerships across the industry.

Their core products are Cimzia®, Vimpat®, Neupro®, Keppra® and Briviact®, and they are preparing the launch of a potential medicine to help patients with osteoporosis.


We use cookies to ensure that we give you the best experience on our site. For more info click here